Related references
Note: Only part of the references are listed.Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
Carlo Visco et al.
LEUKEMIA (2021)
Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy
Tycel Phillips et al.
BLOOD (2021)
BRUIN MCL-321: A Phase 3 Open- Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naive Mantle Cell Lymphoma (Trial in Progress)
Toby A. Eyre et al.
BLOOD (2021)
CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS
J Depaus et al.
HEMATOLOGICAL ONCOLOGY (2021)
Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).
Michael Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Initial results of the combination of PI3K delta inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.
Jacob Drobnyk Soumerai et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
Hun Ju Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Outcomes in mantle cell lymphoma with central nervous system involvement.
Nicole McLaughlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
Michael Roost Clausen et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
Melissa Hopper et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City
H. Miyashita et al.
ANNALS OF ONCOLOGY (2020)
COVID-19 outcomes in patients with hematologic disease
Florent Malard et al.
BONE MARROW TRANSPLANTATION (2020)
Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
Hun Ju Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zhilin Zou et al.
CELL AND BIOSCIENCE (2020)
BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas
Magdalena Klanova et al.
CANCERS (2020)
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Bhawana George et al.
CANCERS (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Management of Drug Resistance in Mantle Cell Lymphoma
Gael Roue et al.
CANCERS (2020)
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Robert Verity et al.
LANCET INFECTIOUS DISEASES (2020)
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study
Julio Garcia-Suarez et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Antibody-Drug Conjugates for Cancer Therapy
Umbreen Hafeez et al.
MOLECULES (2020)
Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma
Neeraj Jain et al.
BLOOD ADVANCES (2020)
Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis
Yazeed Sawalha et al.
BLOOD (2020)
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study
Michael Wang et al.
BLOOD (2020)
Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible
Mats Jerkeman et al.
BLOOD (2020)
Oncogenic MALT1 Promotes Cell Survival and Mediates Ibrutinib Resistance and Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
Vivian Changying Jiang et al.
BLOOD (2020)
Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)
Amitkumar Mehta et al.
BLOOD (2020)
Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
Maria Lia Palomba et al.
BLOOD (2020)
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties
Peter Dreger et al.
BONE MARROW TRANSPLANTATION (2019)
A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma
Hun J. Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Peter Martin et al.
BLOOD (2019)
IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA
C. Rusconi et al.
HEMATOLOGICAL ONCOLOGY (2019)
Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient
Lauren Fontana et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2019)
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
Franck Morschhauser et al.
LANCET HAEMATOLOGY (2019)
A Systematic Review of the Epidemiology and Economic Burden of Mantle Cell Lymphoma (MCL)
Keri Keri Yang et al.
BLOOD (2019)
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
Jennifer Woyach et al.
BLOOD (2019)
Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial
Franck Morschhauser et al.
BLOOD (2019)
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Brad S. Kahl et al.
CLINICAL CANCER RESEARCH (2019)
Classification of aggressive and classic mantle cell lymphomas using synchrotron Fourier Transform Infrared microspectroscopy
Magdalena Kolodziej et al.
SCIENTIFIC REPORTS (2019)
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma
Simon Rule et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Rajat Bannerji et al.
BLOOD (2019)
Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor
Anthony R. Mato et al.
BLOOD (2019)
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
Stephen J. Schuster et al.
BLOOD (2019)
Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
Sasanka M. Handunnetti et al.
BLOOD (2019)
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Simon Rule et al.
HAEMATOLOGICA (2019)
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
James N. Gerson et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
Rishu Agarwal et al.
NATURE MEDICINE (2019)
Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
Vera Dufner et al.
BLOOD ADVANCES (2019)
Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead
Ming Sun et al.
HELIYON (2019)
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
Marion Subklewe et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2019)
A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma
Madeliene Parrott et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials
Rishu Agarwal et al.
LEUKEMIA & LYMPHOMA (2018)
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis
Chintan Shah et al.
LEUKEMIA & LYMPHOMA (2018)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Bispecific antibodies: design, therapy, perspectives
Sergey E. Sedykh et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
Tadeusz Robak et al.
LANCET ONCOLOGY (2018)
Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS PhaseI Clinical Trial
Steven Le Gouill et al.
BLOOD (2018)
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
June H. Myklebust et al.
BLOOD (2017)
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom
David L. Tucker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Erden Atilla et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2017)
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a real world study
Narendranath Epperla et al.
HEMATOLOGICAL ONCOLOGY (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
Michael Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Proteasome inhibitors: structure and function
Ana T. Nunes et al.
SEMINARS IN ONCOLOGY (2017)
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
E. Mejstrikova et al.
BLOOD CANCER JOURNAL (2017)
Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas
Shuangshuang Fu et al.
ONCOTARGET (2017)
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2017)
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies
Simon Rule et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Temsirolimus acts as additive with bendamustine in aggressive lymphoma
Anna-Katharina Zoellner et al.
ANNALS OF HEMATOLOGY (2016)
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Harriet S. Walter et al.
BLOOD (2016)
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Martin Skarzynski et al.
CLINICAL CANCER RESEARCH (2016)
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A. Patnaik et al.
ANNALS OF ONCOLOGY (2016)
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
David Chiron et al.
BLOOD (2016)
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
Nakhle S. Saba et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Marek Trneny et al.
LANCET ONCOLOGY (2016)
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Maria-Elisabeth Goebeler et al.
LEUKEMIA & LYMPHOMA (2016)
Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program
Vittorio Stefoni et al.
BLOOD (2016)
The Effects of PI3K-δ/γ Inhibitor, Duvelisib, in Mantle Cell Lymphoma in Vitro and in Patient-Derived Xenograft Studies
Jack Wang et al.
BLOOD (2016)
Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results
Georg Hess et al.
BLOOD (2016)
Pre-Clinical Evaluation of the PI3K-p110β/δ Inhibitor KA2237 in Mantle Cell Lymphoma
Shengjian Huang et al.
BLOOD (2016)
MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
David J. Andorsky et al.
BLOOD (2016)
SYK Inhibition Disrupts the Cross-Talk Between B-Cell Activation Factor (BAFF) and B-Cell Receptor (BCR) and Thereby Antagonizes Mcl-1 in Chronic Lymphocytic Leukemia (CLL) B-Cells
Cody Paiva et al.
BLOOD (2016)
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
C. Y. Cheah et al.
ANNALS OF ONCOLOGY (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Long-Term Sustained Disease Control in Patients With Mantle Cell Lymphoma With or Without Active Disease After Treatment With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
Jennifer E. Vaughn et al.
CANCER (2015)
Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas
Elise A. Chong et al.
CLINICAL CANCER RESEARCH (2015)
Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review
Annete Njue et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Genetically modified T cells in cancer therapy: opportunities and challenges
Michaela Sharpe et al.
DISEASE MODELS & MECHANISMS (2015)
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Tadeusz Robak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways
Xiaoxian Zhao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial
Constantine Tam et al.
BLOOD (2015)
An Overview of Bortezomib-Induced Neurotoxicity
Cristina Meregalli
TOXICS (2015)
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
Holbrook E. Kohrt et al.
BLOOD (2014)
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Brad S. Kahl et al.
BLOOD (2014)
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Jiao Ma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
Lenka Kubiczkova et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Jennifer A. Perry et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial
Michael (Luhua) Wang et al.
BLOOD (2014)
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1
David Chiron et al.
CELL CYCLE (2013)
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
Andre Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation
Carlo Visco et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
Robbert Hoogeboom et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
Munevver Cinar et al.
LEUKEMIA RESEARCH (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard et al.
BLOOD (2012)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Functions of the Lyn tyrosine kinase in health and disease
Evan Ingley
CELL COMMUNICATION AND SIGNALING (2012)
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang et al.
LANCET ONCOLOGY (2012)
Therapeutic Utility of PI3Kγ Inhibition in Leukemogenesis and Tumor Cell Survival
Thomas Diacovo et al.
BLOOD (2012)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity
Abdirashid A. Warsame et al.
BLOOD (2011)
Negative Selection by IgM Superantigen Defines a B Cell Central Tolerance Compartment and Reveals Mutations Allowing Escape
Bao Hoa Duong et al.
JOURNAL OF IMMUNOLOGY (2011)
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
Stephen M. Ansell et al.
LANCET ONCOLOGY (2011)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications
T. Weichhart et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Bruton's tyrosine kinase and phospholipase C gamma 2 mediate chemokine-controlled B cell migration and homing
David J. J. de Gorter et al.
IMMUNITY (2007)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
Development of effective immunotherapy for the treatment of patients with cancer
SA Rosenberg
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2004)
Progress in the development of immunotherapy for the treatment of patients with cancer
SA Rosenberg
JOURNAL OF INTERNAL MEDICINE (2001)
Share Paper
